AVADEL PHARMACEUTICALS PLC — Director's Dealing 2018

Feb 7, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2018-02-07

Reporting Person: D'SILVA DHIREN (VP Irish & European Operations)

Holdings (Non-Derivative)

Security	Shares	Ownership
ADSs	15000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$23.53	2025-09-15	ADSs (50000)	50000	Direct
Stock Option (right to buy)	$10.4	2026-12-14	ADSs (80000)	80000	Direct

Footnotes

F1: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs are represented by American Depositary Receipts.

F2: Represents 15,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.

F3: Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 09/15/2015 grant date.

F4: Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.